NCT04881916View on ClinicalTrials.gov

Immune and Genomic Markers in ALK+ NSCLC

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Anaplastic Lymphoma Kinase Gene TranslocationNon-Small Cell Lung Cancer
Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
collaborator

LUNGevity Foundation

OTHER

collaborator

Addario Lung Cancer Medical Institute

OTHER

lead

Massachusetts General Hospital

OTHER